CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

During a live event, Neil M. Iyengar, MD, discusses how genomic risk scores and menopausal status guide complex adjuvant ...

Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer” The following represents disclosure information ...

VERITAC-2 trial shows vepdegestrant improves progression-free survival in ESR1-mutant breast cancer, marking a clinical milestone for PROTAC therapy. The trial did not reach statistical significance ...

A study led by researchers at the Fujita Health University School of Medicine, in collaboration with Chiba University's Graduate School of Medicine and Fukuoka University, Japan, revealed that ...